understand the disappointment but as some have pointed out previously, ARDS was an add-on for meso. i see it as a matter of time sort of thing, the FDA can only put the treatments off so many times before they are forced to cave as long as they continue to prove successful. managements recent failures have been disappointing but this is groundbreaking technology and meso is in the best position globally to capitalise on its potential.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-244
-
- There are more pages in this discussion • 832 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |